Prognosis of Patients With Early Breast Cancer Receiving 5 Years vs 2 Years of Adjuvant Bisphosphonate Treatment: A Phase 3 Randomized Clinical Trial

IMPORTANCE: Bisphosphonate treatment in patients with early breast cancer has become part of care, but the optimal treatment duration is still unclear. OBJECTIVE: To compare 2 vs 5 years of zoledronate treatment following adjuvant chemotherapy in patients with early breast cancer. DESIGN, SETTING, A...

Πλήρης περιγραφή

Αποθηκεύτηκε σε:
Λεπτομέρειες βιβλιογραφικής εγγραφής
Τόπος έκδοσης:JAMA Oncol
Κύριοι συγγραφείς: Friedl, Thomas W. P., Fehm, Tanja, Müller, Volkmar, Lichtenegger, Werner, Blohmer, Jens, Lorenz, Ralf, Forstbauer, Helmut, Fink, Visnja, Bekes, Inga, Huober, Jens, Jückstock, Julia, Schneeweiss, Andreas, Tesch, Hans, Mahner, Sven, Brucker, Sara Y., Heinrich, Georg, Häberle, Lothar, Fasching, Peter A., Beckmann, Matthias W., Coleman, Robert E., Janni, Wolfgang, Rack, Brigitte
Μορφή: Artigo
Γλώσσα:Inglês
Έκδοση: American Medical Association 2021
Θέματα:
Original Investigation
Διαθέσιμο Online:https://ncbi.nlm.nih.gov/pmc/articles/PMC8227465/
https://ncbi.nlm.nih.gov/pubmed/34165508
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1001/jamaoncol.2021.1854
Ετικέτες: Προσθήκη ετικέτας
Δεν υπάρχουν, Καταχωρήστε ετικέτα πρώτοι!

Παρόμοια τεκμήρια